<SEC-DOCUMENT>0001193125-13-474252.txt : 20131216
<SEC-HEADER>0001193125-13-474252.hdr.sgml : 20131216
<ACCEPTANCE-DATETIME>20131216122135
ACCESSION NUMBER:		0001193125-13-474252
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20131216
FILED AS OF DATE:		20131216
DATE AS OF CHANGE:		20131216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theratechnologies Inc.
		CENTRAL INDEX KEY:			0001512717
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35203
		FILM NUMBER:		131278319

	BUSINESS ADDRESS:	
		STREET 1:		2310 ALFRED-NOBEL BLVD.
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H4S 2B4
		BUSINESS PHONE:		514-336-7800

	MAIL ADDRESS:	
		STREET 1:		2310 ALFRED-NOBEL BLVD.
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H4S 2B4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d645012d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C.&nbsp;20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 6-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Report of Foreign Private Issuer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Rule 13a-16 or 15d-16 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>under the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;16, 2013 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number 001-35203 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>THERATECHNOLOGIES INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Translation of registrant&#146;s name into English) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2310
Alfred-Nobel Boulevard </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Montr&eacute;al, Qu&eacute;bec, Canada </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">H4S 2B4 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Address of principal executive offices) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form
20-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Note: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Note: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required
to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>THERATECHNOLOGIES INC. </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:25pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated December 13, 2013</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:36px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">THERATECHNOLOGIES INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Jocelyn Lafond</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jocelyn Lafond</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Legal Affairs</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: December&nbsp;16, 2013 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d645012dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <DIV STYLE="position:relative;float:left; margin-right:1%; width:10%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g645012g21v86.jpg" ALT="LOGO">
 </P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;
</FONT></P></DIV><DIV STYLE="position:relative;float:right; width:86%;padding-right:9px;padding-bottom:8px;overflow:hidden;padding-top:3px">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g645012g78y27.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THERATECHNOLOGIES
REGAINS U.S. MARKETING RIGHTS TO </B><B><I>EGRIFTA</I></B><B><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Montreal, Canada &#150; December&nbsp;13, 2013</B> &#150; Theratechnologies Inc. (TSX: TH) today announced that it has reached an agreement with EMD Serono to regain all rights under the current
collaboration and licensing agreement entered into in 2008 with EMD Serono, including commercialization rights for
<I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (tesamorelin for injection) in the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;This is a significant moment in the company&#146;s history. Having marketing rights for our product in the U.S. will give us the platform we need
to accelerate growth and drive profitability. From a R&amp;D-focused company, we are now evolving into an integrated specialty pharmaceutical entity&#148;, said Mr.&nbsp;Luc Tanguay, President and CEO, Theratechnologies Inc. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;EMD Serono is proud to have brought<I> EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> to market, making it available in the U.S. to the HIV community,&#148; said Paris Panayiotopoulos, President and Managing Director. &#147;We are confident that it
will be in good hands with Theratechnologies. We will work closely throughout the transition to ensure minimal disruption for patients. EMD Serono remains committed to the HIV community.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">EMD Serono agreed to terminate its collaboration and licensing agreement with Theratechonologies in consideration of an early termination fee of USD
20&nbsp;million payable over a five-year period starting on the first anniversary of the closing date. Starting in 2016, Theratechnologies will also pay an undisclosed, increasing royalty based on annual net sales. Royalties will be paid until a
cumulative aggregate amount is reached or until January&nbsp;1, 2024, the first of these events to occur. National Bank Financial acted as the exclusive financial advisor to Theratechnologies for this transaction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of the termination of the collaboration and licensing agreement, Theratechnologies will be responsible for all
operations in the U.S. relating to <I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, including the conduct of the post-approval commitments
mandated by the U.S. Food and Drug Administration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The transaction represents a cornerstone of the Company&#146;s
business plan to maximize the commercial potential for <I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in the United States and elsewhere. By
regaining rights to <I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, we will have full control over a product that we know intimately,&#148;
added Mr.&nbsp;Tanguay. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Key resources to support U.S. activities </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To add commercial and marketing expertise to its management team, Theratechnologies has hired Mrs.&nbsp;Lyne Fortin as Chief Commercial Officer. Mrs.&nbsp;Fortin is a seasoned pharmaceutical professional
who holds a M.B.A., a B. Pharm. and a Certificate in Chemistry. She has spent close to 30 years working in various positions at Merck&nbsp;&amp; Co. in Canada and in the United States. As Vice President of Sales and Marketing, she was instrumental
in developing strategies in several therapeutic fields and niche products including treatments indicated for people living with HIV.
</FONT></P></DIV><div style="clear:both; height:0px; font-size:0px">&nbsp;</div>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Theratechnologies has retained the services of inVentiv Health to establish and manage
its operations in the United States. The services provided by inVentiv will include sales force, marketing support, communication, regulatory, compliance, reimbursement and market access. All decisions regarding the commercialization of
<I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> will be made from the Company&#146;s head office in Montreal, Canada. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transition </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The closing of the
transaction is expected to occur during Theratechnologies&#146; second fiscal quarter of 2014 to allow for a proper transition. Until closing, the original agreement will continue to apply and measures will be implemented, in collaboration with EMD
Serono, to ensure a seamless transition for patients, pharmacists, physicians and other stakeholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conference call for analysts
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Theratechnologies will hold a conference call today at 9:00&nbsp;a.m. (ET) to discuss this morning&#146;s announcement. The call will be
hosted by Luc Tanguay, President and Chief Executive Officer. The conference call will be open to questions from financial analysts. Media and other interested individuals are invited to participate in the call on a &#147;listen-only&#148; basis.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The conference call can be accessed by dialling 1-800-750-5857 (North America) or 1-416-981-9000 (International). The conference call will
also be accessible via webcast at <U>www.theratech.com</U>. Audio replay of the conference call will be available until December&nbsp;27, 2013, by dialling 1-800-558-5253 (North America) or 1-416-626-4100 (International) and by entering the playback
code&nbsp;21699740. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Theratechnologies </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Theratechnologies (TSX: TH) is a biopharmaceutical company which specializes in the development and the commercialization of innovative therapeutic peptide products. Further information about
Theratechnologies is available on the Company&#146;s website at <U>www.theratech.com</U>, on SEDAR at <U>www.sedar.com</U> and on the SEC&#146;s website at <U>www.sec.gov</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Information </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains certain
statements that are considered &#147;forward-looking information&#148; within the meaning of applicable securities legislation, which statements may contain such words as &#147;may&#148;, &#147;would&#148;, &#147;could&#148;, &#147;will&#148;,
&#147;intend&#148;, &#147;plan&#148;, &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;, &#147;expect&#148; and similar expressions. This forward-looking information includes, but is not limited to, information regarding
Theratechnologies&#146; growth, profitability and the commercial potential of <I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. Theratechnologies
disclaims any liability resulting from the statements made by EMD Serono, Inc. in this press release. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forward-looking information is based
upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Theratechnologies&#146; control that could cause actual results to differ materially from those that are disclosed in or implied by such
forward-looking information. These assumptions include, but are </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
not limited to, the fact that Theratechnologies will have all the distribution network, licenses and permits necessary to continue the distribution of <I>EGRIFTA</I><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> seamlessly on and after the closing date, that sales of <I>EGRIFTA</I><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> will not decrease during the transition period, that Theratechnologies will be able to increase sales of
<I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> overtime and control its expenses, that <I>EGRIFTA</I><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> will continue to be reimbursed by the same third-party payors in the United States, that no shortage of
<I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> will occur, that our third-party manufacturer will be able to manufacture and timely deliver
<I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> to meet market demand, that no conflict will occur with our third-party service providers, that
our intellectual property is adequately protected and that no event will occur having the effect of enjoining the closing of the transaction described herein and that <I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> will not be withdrawn from the U.S. market. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">These risks and uncertainties include, but are not limited to, the risk that an event occurs resulting in the issuance of an order having the effect of enjoining the closing of the transaction, that
demand for <I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> decreases, that a product shortage occurs as a result of problems with the
manufacturing process of <I>EGRIFTA</I><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> or our third-party manufacturer, that<I> EGRIFTA</I><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is no longer on the list of reimbursed drugs by some or all of the current third-party payors, that the distribution
network is not fully in place by the closing date or that all licenses and permits are not obtained by Theratechnologies by such date and that unexpected events occur resulting in unplanned expenses in the operation of Theratechnologies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We refer potential investors to the &#147;Risk Factors&#148; section of our Annual Report on Form 20-F dated February&nbsp;26, 2013 available at
<U>www.sedar.com</U>, <U>www.sec.gov</U> and <U>www.theratech.com</U>. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements
reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be
required by applicable law. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-30- </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Information: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Denis Boucher </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NATIONAL Public Relations </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">514-843-2393 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g645012g21v86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g645012g21v86.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X004:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C`M8S`V,"`V,2XQ,S0W-S<L(#(P,3`O,#(O,3(M
M,3<Z,S(Z,#`@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-C0P-3(R1C%%,30P,3%%,4%"-3-"0T,R1C%$
M.$%#-T0B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-C0P-3(R1C!%,30P
M,3%%,4%"-3-"0T,R1C%$.$%#-T0B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HS861E-C0P-"TP-&8V+30X,F0M.#5A,BUA
M-V8R86%D-S`V8CDB('-T4F5F.F1O8W5M96YT240](G5U:60Z8V$V8V$T-C<M
M,#@V-BTT,SDU+3@R,6(M-3`Y9&$V9#<W.68P(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YA=&5R:6-K/"]R9&8Z;&D^(#PO<F1F.E-E<3X@
M/"]D8SIC<F5A=&]R/B`\9&,Z=&ET;&4^(#QR9&8Z06QT/B`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@4')E<W,@4F5L
M96%S92YD;V,\+W)D9CIL:3X@/"]R9&8Z06QT/B`\+V1C.G1I=&QE/B`\+W)D
M9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C
M:V5T(&5N9#TB<B(_/O_M`$A0:&]T;W-H;W`@,RXP`#A"24T$!```````#QP!
M6@`#&R5''`(```(``@`X0DE-!"4``````!#\X1^)R+?)>"\T8C0'6'?K_^X`
M#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"
M`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#_\``$0@!:P`R`P$1``(1`0,1`?_$`)X```("`@,``P``
M```````````*"`D'"P0%!@$"`P$!`````````````````````!````8!`@(#
M!A$%"0T)`0```0(#!`4&!P@)`!$2$PHA%!4U-A<Q(C(S8S1D%E8W5Q@X6!DY
M&D%A56768B/3=I:7MYA944)24R0EE=5FMG>GUW&"HD-SHU34I3H1`0``````
M``````````````#_V@`,`P$``A$#$0`_`'^.`.`3SUL[OFXMKEUIY+VS]C"I
MU<KW#;EU7=1>M2S)1<C5J)--72T3/MZY,SC*7J%9A*_+MG,<#\[":F9N0;.`
MB&@)M>^5PI_W=-F'<,TCZ(,I:]M5.[;E[4)D^D3..H]WCF&<90"KKJW^\0-+
M=ECKM/9,8JM&L3X<ZY(J-:;$6(F"?5I`("`;!32PY<O=,6G)X\<+NWCO`^(7
M+IVZ64<.73E?'U>57<.%U3'57765.)CG,(F,81$1$1X"%N\[J,U2:1=N;4'J
M9TA!05,LX7BX&XO&^0ZR_M<4?'Z=ACHR^/8R,93$.D2=K\%)'E$5'1EVH),5
M2'1.)RB4*D/Q+N/O@]#?<U?/Y_+])WY"O&'BSV3US\_`-<\!AW419YZDZ?\`
M.ESJH*#:*CAW)MGK8(\^N&>@*5-RL."71YFZSP@T3Z/+N\^`79[(MC"H5?:3
MA,KQK9%QD'/V=,S7')]E6Y+S4S+5>W/*#!-9)^?I.5D&$-72N$DSF$"+/EU`
M#I+'$0RSVK+[DG4W_''3[_3G0N`NTTJHJ-]+^F]!8HD61P)A]%4@\A$BB>/:
MZ0Y1$!$!$IBB'<X".V[&M`H;7^X8I9CMDX3YE^I0CLSL>2`J*XBMB3(AORB=
M1^=(I`#NB<0`.`TSWA.Y?XR4^C9X,]2KY&_XOT?%?Y_4\!O9>`XKYDTDV3R-
MD&R+QA(-7#)ZT<$!1NZ:.TCH.6RZ9@$JB*Z*ABF*/<$HB'`)*:*]5+?LWFLK
M-NVMK=1GZSH%SQE2P9LT/ZG`AY*3IM0C[<X9MI*FVY=BW=.$8R-;I,F<P=`J
MBL++M3/%D/!\H1VB%AW:;,FXXS!L-ZAK]B:^TW)M&G+1IZ>0UPH-FAK?691L
MIG*@&(LQG(!X_C7)!`X>H4'D(\A[O`7U8!EXFO:7\'S4_*1T'#Q>"\7NY.6F
M'K:,C8YJA0X(RSE^^>JH-6;=$H<S'4.4I0]$>`47WT]U=AN*N8#92VII9KJ-
MS#J0N<-6,\91H#LLEB^H4:OS#2;E:JPO3$'$7)QQ'46F^M4VU.K$Q<(S6;=<
MX7<K)M@L%_#/Z6OTZ'W67V?7BDOQF_6:]7Y4>YO4_GX!F#@#@(Z:H=).F_6E
MBJ5PIJCQ!3\RXVEE"N30-K8J'<1,FFF=)"<K$\P696&I6)JFJ8J4A&.FCQ,I
MS%*H!3&`05<SKV,_2W9@LT?IEUE:D=/%+MCA%Y+XOLS:*S)0%5FCA-Y'MP9D
ME\;3+YG'.D4SH#*/)1RD8A3=:8P`/`>99=D!L5]/%PVI_=QU3YJQY%)L6:%*
M:5A_'"E%QZ2+=LQC'^0<N95A8A)JV1*D@4L0JFD0I0*7D4`X!C3;UVG-#FV'
M592!THXC0@++96C9E=LM6Z04N&7+NW:G(JDTG;E())J,H<'"95O!<6A'1!5P
MZTK4%.9Q"R#@#@.%)R3&&CI"7E'23&,BF3N2D7JYN@@S8L4%'3MTL;D/12;M
MTC',/Y`#@*2=DG=#S;NKTK5'FRWX8IN-L!4;4-8\::;;?`RL\:QY#J$8"DH?
MWWPDL#MDG,UZ`E(?OF19.4FKQX\61(T1[U,=0+OUEDFZ2JZZJ:"""9UEEECE
M32123*)U%55#B4B::9"B)C"(``!S'@$C\U;R>Z_NJZOLKZ3-B*NTNG82P;(+
M0]]U>W*)KKYI-K(O747[XPL5[BK'5*G3IZ2CW)8!BQAI*R2S5N=\7JT>M0;A
MP;9KN[0[LF2E&RIN@-,6ZYM$$_:H2K9(R9BAE7/?ABSPZ\1:(.FTW7*5BN0C
M950YQ[T)/P[R&DUP*Q(^9N7"1P!J'[2#19\O-.^B!\_'VRI]%CY4?6_:'N;V
MW['P$X>`QEFNGR60\-9;H$,N1M,7G&5]I\4Y4/U:;>2LU5E85BNHIS+U9$G3
MTAA'F'(`Y\`M3V1_*U(5VW[-I5<.6L#J`TL:@\Q5G-F-Y`Q&EMA75DMCJ9AY
MY_%*=!V,:N<SB(!?HB4KR'71,(&3`!#/_:6-QR"T0;>M_P`5T^Q!\YS5]$R6
M#L-U*%>&&WMH"U)EA\EY";,&0*2:+&OU5\LP9N$P*8TY),B)B(]/HA)S8FV]
MFVV_MQX2PY.5]K#9INT:7,&H1R5!,LFOE2^-FS]S7Y-P"*2JQL>5XC"OD*(B
MF`QIU"]U4PF#/V[36:/;ML#<"A,CI,U*B.D#/\L],^ZOJ6DC7,:V&Q5N23%7
MTI'L59HIFY;'#D8CA(ABB!@`0#3B^>[-OZ=L/T2_,C[:<_$E^@O5>3WL7K7Y
MN`WHG`'`+5[B79SJ5J=U&3.MC1;JHRKMYZN;5UR]_N^)!F`JF1)-P")7L_*1
MM4ME!LU=L\V"!!DW3*3.TDE"=<X9*.CJN%`QQH'[,U6<)ZG*_K5W`=6^2-Q'
M491Y!C,8[7R0WGRTZK3\,N9Q7K),J7.Y7ZU7F6J[H>^(E%P[9QD>ZY+=Z*JD
M142!IO@*K]YS2'J;UW[?F8-*^E3)&/\`&5]RHM7HZR2F1@GF\+8L>Q<D6;L-
M';3E=CYE_6G=K>1S-LL\%B\2-'BY;G3*"_6IA5U^&#TX_"1O]U7\Q+Q87X^?
MK-^H\8^X_P#Q<`TKP!P$$-;.YIH:V[X%A-:NM0E-Q8]FFBSZMTHWA*T9)M+5
M`YT3NZ_CNI,9NWOXX')!2,][T*Q35]*=8H\!1Y+]L;VB8U\LT91FK2PMTC&*
M24B,+UA%BX`!Y`=%.?RC!R12G#NAUC<@\O1`![G`=9^,JVE/@CK'_F=Q]_UH
MX#A/^V6;5I4!\!8SUH6*0$>BC&M,2XX;++*#R!-,JB^9Q(!E##R#T>[P$Q_Q
M#VGWZL^J+[O_`.T.\GJ3\6/P`\L?C/\`<WB_W7P#!?`>6O-NC*!2;C>YKI^!
MJ35K!;I;J^76>#*W$NYE_P!7SYAT^]61^7Y^`2#V+]N+'6\-<,][S^YC`(ZA
MK%E[.-PKV"<-7=RZE,8U.JTI9JR*YEZT8R<?982K]>6N04,[!6+:M8I9=P@X
M77240"27:G-,FG["^AC2A=,68&PSB^OT;7Q@TMI\WN+*-34_>@^JN24G,:Y"
MNP4<52'6=-D04;'`4%#`3I%$2AP#1)-)FDQVB19/3-IW<(.4BJ$4##&-E$UT
M5B`8I@'WM"!TU4S?]@@/`+;[NFV'$:`49+>5VIJS7-.N?],+56YZ@<(4N#:Q
MF#=1>!P?-E<FQ\YCJ/30@(&2BX8#/WIHY%HBY9-EG!")RJ#1X4)"?B;-$WZ(
ME/NV?GZ^.V'EC]5GVE\8WNOVK['P#)W`>$RC2T\D8RR+CM9<&J-]HENI:KD>
MER;IVFOR$&HN/0`3\D2OA-W`$>YW.`6I[)I>TXO;[RMH_M)`A\SZ*=5>9L79
M/J3@`2DHD]@L3FQQTBNW,/7%:O+!X:8IF,4`,K%J@'/H\!8MOOZ.YK7'M8:J
M\*4Z)<3F2(ZH,\L8OBF1.MD)6\XCE6=Z8P,:CR$5I*UQ<0\B$"`("95^`<_R
M"'3;&.Y!CG<7T%8=LS"T1JV=\2TJKXKU&T%=X@G;*UD.GQ#>`7LK^&.L9^G7
M<A)1OA6/=]$4#]>JWZ??#5PFF&3-Z'4_A[2IMFZP[IF&>AX]K=,"Y3Q'1ZW(
M.VR<CD#(>4*/.TNJU""CE%".95P[D)@JSL$2G%K'(.'*G121.8H:D#YFNJ#X
M"6SZ"WSO_:K[Z-/PR]#R;_=>M<!O!^`.`B[BC1;I@P=G;.VIG%.(J_3,XZF'
M<2^S=?HQW-F?7ES"H((LE'48[E',%%B95#OA?O%JU[[>**N%^L654.8)1<`J
MUKU[,30\R9_L>KS;VU2Y%VZ]0USD)";O2>-@L!,=VJ>EG7?TS-Q"5+ME'M>/
M)&POS"XD4V3MY%.5OWPK!)0RIU`C5@[LH-YR3F>K9>W7MPS*VN.(I#U)U#XI
M&3R$M&SB:*I'`Q5BR'D*Z6"R1]5?*HD!Y&PS&-7<%`0!\GS'F#=/F0PU\E6/
M/BM\R'D?`_$U\E7M#XO/U/[0]BX#*/`'`+*[I/:"I33=J(1V_=NO3O)ZX->;
MDR32Q5F':S<SC[%,BY:(OB1%A9U$Y)ZVV>/8N$W$FT1=Q;"%0.!GK]-4BK<@
M4CZ]=1O:U=-^F.WZV=0F8L,Z8<45-_4$)3&N-XC`4O;XA2]6:+K$(W;QH5#*
M"[DK>5F$"N".[$LLDF)A$#B40X!\'3S9YR[8`P;<[.^&3LMMP]C.SV&2,BW;
M#(3D]2X25EGPMVB2#5N+M^[44Z"1")DZ7(I0``#@(G;J>N&V[<NB/+&K^I8.
M7U`+8K4K!IBCI7(M&390MFL,?5SVM_,!7;0Y4BH"3EVIW2*#0RHMSG/TB%3,
M8`C+]N9I+_\`FJ?=<?:B>WD/B]^3CU'EQ[#Z/[G@+K.`QAFZ^+XLPOEW)S5L
M5XYQSC"_7QNT,'2*Z7J%4EK`BV,7\I5U(\"B'Y^`6*[))IYK">A_(VOJW)(V
MS4MK5SGEN=R#DV612=64U:JMWD(8M:0D52'=MV4K>64M-O@*H`/'+M$50-WL
MAT`DKVK+[DG4W_''3[_3G0N`NQTH`)=+6FL#`)3!@'#@"4P"4P"&.ZX`@(#R
M$!`?R#P$<]VJNPUKVO-PN$GR)&C%]&FHQVH*W5@1)U$8JM$Q&N"F4Y%(LVDV
M"*B9O1*H4!#N@'`:=+SVY"_3DA]#[S)>V%?B]_0?H>+_`&/U'`;S?@.BM%;B
M+C6;%4)]L#V!M4%+UN;9B/('<1.1[B,DFPB(&Y`NS='+SY#Z/`*`[#&J"O[8
MN:]0.Q%K0L3#%^1,;9PMEVT=7JW+EA:?G'%V3'*<Q%0L%8)`S>+)8)I0GAB,
M0.8AGZ\D\CRCWZQ%!0)V=JR^Y)U-_P`<=/O].="X"\/33]'+`'_!/%7^XL#P
M"WO:;=S"IXYTV3FV1I\?^=+7!K;&O8@0Q91^4]8J5C>]3#./FUK&V8*F".L&
M2VAO`,-&+B5RY1D5GG1!!`IE0@A^$\FOT_6?ND?,[[9;?>%?IKVY\7?NWU7`
M/.\`<!5UN:[0FC;=8H<37-1U2DHO(%-:OD,99SQ\[:0&5L?]^B991BREW#)^
MPL%76>B"ZL1*-W;$5>:J147`@N`*]:K.SL[Y[W`=ITB8FW/JOJGTA3SN!.CB
MK45,VZKV9FPJ4\SLE48L'DW6LO&A4(.4C6YR)1MA8-5!2Y"@5,>KX#*$?MS]
MK3S%7X#$N0]Q;"&GC%,+78JH%=8RL4?7;&SKD-&-H9FC&R&(,(PEM>/$XUJ4
MG24G&9E3AS.J`F$W`6U[4O9X=,&V]<SZB;Y<;)JWUG28R#MYJ!RBT%)"J2$X
MW,A/.L<5-W)V!>(F98BZR;F;DI"3F5DE5")KMD5ED3@P?P"SLIVM;9OAY.1B
M7N1LWE>1;]Y'.RIX(MJA"N6+A1JN!%"J<CD!5(>0_E#@.#^+GV9OE'SE_,+;
MOX3@#\7/LS?*/G+^86W?PG`'XN?9F^4?.7\PMN_A.`/Q<^S-\H^<OYA;=_"<
M`?BY]F;Y1\Y?S"V[^$X"9?V^NW;\+<G_`$,/GZ_%=._1Z_2GKOE1^J_7OS\!
M,Y?;6VZW2ZSESH,T:N'+E95PX<+:9<+JK+KKG,JLLLJ>EF.HJJH83&,(B)C"
M(CW>`_+[,_;E^H-HQ_JPX5_8K@#[,_;E^H-HQ_JPX5_8K@#[,_;E^H-HQ_JP
MX5_8K@#[,_;E^H-HQ_JPX5_8K@#[,_;E^H-HQ_JPX5_8K@,C?,OT??55TX_%
MEYE?B3QM\3OR4^37Q;_J3Q;[#P$EN`.`4\W%=]+5?<]6]DVR=E#`S'4;JDII
MG<;FG-TXS:2N-\-RK%PBSG(J+3EI*%IG?E1>."-I6<L+XD*RD^<>FT?.>D"8
M4W[DNG;M*.D'1Q?]=.J;=FDHQ"H2U';R^(L`9.O54DT%[]=(:I,VZ)Z!0\9T
M-J:*>3::BJ;85T.J3,5-0X]'I`_/IJFI>RZ<L`6*P23R9GI_">*IJ;F)%<[F
M0E9>5HL"^DI)^Y4$5'#Q\]7.JJ<W=.<XB/H\!#S=ZU=YZT'Z`LWZL=.N-Z)E
M2]8>;5V;DJSD-U/(P#:G2-ACH"Q646=<=QDG,*U=.53?*-"O60'9HKGZX#$*
M0X5[?B*=/?Z&;?=%_:6^W%_++Y`/0\?_`+OU7`,<<!B7/MTE<;X)S5D2"2Z^
M;H6)<CW2&0ZOK>NE:M3IF<CTNJY#UG6.V)`Z/+N\^7`+;]D7PI4J]MERFIQ9
M`DQFC5CG;+-NRM?)`"N;',DI-OE:7`PSR1/S7.P:.XZ0DRIB/(7DNX4'F)^X
M&<^U9?<DZF_XXZ??Z<Z%P%V>E),Z6EW3:DJ0R:B>`\.IJ)G`2G(<F/*Z4Y#%
M'NE,4P<A#\@\!'?=C8P<EM?[AC.QBW+#J:+]2BCHSDY4T2*-\16QRS.)S^E(
M<CY%,2#Z('`.7=Y<!IK??]>?TC)?1=]X/JG?D-^CO5>+?S>L_FX#>K<!ULS$
M1M@B)6!F&B3^(FXU]$2K%<.DB]C9)JJR?-%B@(<TG#58Q#!_<'@$OMJ75I7M
MBS5=G;9<UYSI,78<G<LSV8=">I.XJA%8SLU"R.Y3%M5[+9G0$BZZWD%&*9@?
M+K%8L;&G*,G:J0BV,H%C/:HW[&5V.]1\G%O6DE&R%GT[/F$@P<(O&+YDZS?0
M%FSMF[;G40<M7")RG34(8Q#E$!`1`>`O.TU?1RP!_P`$\5?[BP/`*M=HXW3H
M#*5-)LT:#7R&?]8>KFT5[%.26.-9!M8(_%U1=S;1W+TF:F(L[I@A=K:+`&TF
MT.<"05=!^ZD3-N:'3#O/PK&+?AU"?=2?,\]H+?2X^L)[2\F_<GMG@&]>`.`A
M-KGV\-(VXYBGS1:L\2Q&0H5BHZ>5*S('4A,A8\EW:1$E9J@W:.ZN:KKM8$D^
M^$2G.Q?%2(1VW<)E`G`*BY][(OJ)+C^Q80TI;J^6&6F>Q.F;I?39GY"Y2%"3
M/$2Z,W"&?!0[8C3)9S%R39-=)<M3:*$6(!P[H<^`[A+LX.\]E^,B<=ZE]\.\
M)8<CXYE7UJCCV>SG9V*E99,T8U.%)4Y"TXPK*K8L<@5$A'`KI%``$2&[H"%]
M&USL9:'=J=DYL&&ZS*Y&SQ-1RD99=1.51C9G(JS!T4O?\)44F3%G"X^K3U0!
MZYM&HD<O"`4KUT[ZM,2A<GP$6-9VLS`&@;3W=M3.I6XEI^-*2DW1-WL@$A8[
M58I$5$X&ETN#!9!:?MMA<IF(V;%.0A2$47741;(KK)@I'&]HHWH]:KM_<-LC
M:">6/`Q9)TRKV1<J5[(MU)8DF"YD5CC;(2Q8GQLSDA,00<,&;V6%H?T@N%!#
MI"$BL`]I=SIA+,-,P5O5Z![SH-7R'(H1-2U`1T!=V6'C/E52MS+3T1<$I1PE
M6FBJA.^Y>'G9PC$#@=PV20`ZY`:PO>9,2XPQC+YKR+DNBTG$$#7DK9,9.LUI
MA8>B,*TY11<-)Q:TO7B4,,:_2<I"W5*L)7`JD!+IB<H""R^H/M>.W#CZSNZ#
MINH6H369="NEV$8?%E(+5:5,OD3"F",=-W==C<'Z*BI>15F=<=I*%Y&3,<H@
M(A%61W=^TEZX5"1&A7:7/I>J<XIT8[)^H2&EU)%DP4$Q4Y5E8LU#AS'KA,A!
M`Y@3@9?GRY$*?GW0G]\W'M#WUK\:?=J^]OQQ2_O'?AK\3/DK_P#@^X>`A3O/
M48VYGOO[:VU7;WTDIINQKCJ:U59VKT>Z59M[$HJ:Z2+R*DE&XBJ4[ZJXT9PC
M9P`D69I6AT9$Q3*<Q!Q2JU6LT:M0%,I=?AJG4:K$1]?K-8KL:SAH&`@XEJFR
MC(B'B8]%NQCHV/9HD2112(1-,A0`H``<!'W65H_P=KMTZY'TS:@ZE'VN@9#A
M'3(JSAJ@K,4^QE;KEKU]I[Y4HK0MPJ4@J5TR=)"40,44E.F@HJF<->OH>T\:
MP]V/4+C;9`U69,L\-H\VBI_,K?.,C4I!>/L656=,RF^I>-ZO(.78KH=_,T#A
M"5I4Y'`0U:(\62*9P4G,-A)I@T2:2M%].8432YI\Q?A>"8M$V:B].J[!O99D
MJ90)WU:;HZ([N%NDE0#]\=2CYVY4_OCCP$I>`.`4J3%.([8>X\*B!36G;8*%
M:!4.?6*-TD!7!MTQ]*()5R0$>A^0IO[IN`;5X`X!3G8Z9-`WINT6O0;I`[)J
M(QNV*X`@`H5!Q:LW.%T@,']XJND4YO[I@Y\`V-P!P!P"P^[WLI:T-9>O'"^O
M#0GJZJ.DG*>-L"'PQ*VAZZOD7<E1+8KX]!Y!RE.AY0A&$E7,@.F#I-4R8]`@
M<@,!A$H0J^Q7[2K_`&ZQ_P"7>=/V4X`^Q7[2K_;K'_EWG3]E.`P7C3LWN^GA
MK(N7LN8KW>*10LF9^F&5@S3=ZS/YJC;#DR;CEI-PPE+;((U(%95XT7F71DSG
M[I1<'Y>J'@,Z?8K]I5_MUC_R[SI^RG`'V*_:5?[=8_\`+O.G[*<!8A]G!O*?
MVG8_=R_-Q\K<I?3$^LSXA]7[N\;>Q<`Q[P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P$#=%^Y+I2U^6+435]--NL%MD=,&3GF*\G.I"G3T+`&FT'\W',):IV=RU
M/7;37YU:N/3M%&SH7(H(@JJ@DFJB90)Y<`N+N8]I7TC[?N:G&EJA8WR+K"U/
MQCIM'V;&F'W3!C!4R;=H@NC4['<E6<^Z7NW4*$.I%Q43*+->ET'1FZP=5P&$
M])?:J]-F5,V573]K,TR9QV]KY?GS"-I4YF3K)/'+U[*N091B=EL$G6:!8:>V
MDGJA$4GSB'5B4SFYN7;<@"?@&I.F3_#)ZCI^J#U'^'Z/J/S^AP'VX#$N?'MB
MC<%9ID:?WQ[[6&)<C/:OWH43.O?$UITRO"=[%`0$SCPFFET`#NB;EP"YW9":
MS3(G:!@K+7P9*VV]ZALW3>3WR8D5DU[7'2T77(M"8<>F<&71I,1%*ID4'N)N
M.F`?O@B(6V;M>N**V[MOW47J?5D8YG<ZQ2WE;P\QD`35+.9HN::E?QO')LE"
M*>$$F<Z[+(O$@*;E',7)S>E(80"F_LNNV="8.TILMPC.]?"V:R=:Z\UE57(-
MR0&4MU2Q/;I)S(UQI&/9%$SF.ELHE64LLP\2,5>02DFJ*IA*V`!"QS?GT58B
MUG;8^JJ/R#4X&1N^%L,9)SIAJ[NV2(6&AWS%M3DKLBI"3($[\81]I90*D5)H
M`84'3)T8#E$Y$CIAKD_MWM9WRG6C[K3YA?C1QZCY4/0^,;]<>WO9>`V__`?!
MB@8!*8`,4P"4Q3``@8!#D("`]P0$.`3`ONA_>%V2]2F=\L;/^-Z1JYT-:D;N
M]R=9M(]L6(I-XAO$L!S2`UB&)::5/J,VG2!K&OX-X\46C$F[64CU3,FSLX8?
M2T(;S>_MJ/PS9MV?%D+HIT$8%LR5Q#3]7#*0<]DN92ZI-]'LZX\M5MN:D]8V
M!31[JP3:S%M$1:[@(EL*ZZX*`\;"0L16X:(KM?C64-`P$8PA82'C6R3..BHB
M+:I,8V-CVB!2(M63%F@1)),@`4B9`*```<!3MV@/)V:<;[46JJ/P!B')F8\D
M9<IB^#T(K%U3F[A*5*IY.0<P60;Y.1]>:/I5K`0-$-(I]\II'*F_=-0/T4S'
M.0$V_P`+EJ4^#*_W0WG@]`_TW?J_^U/'7L_J/W7`;,#@#@%2</\`:U]$@9,L
M&%-;&&<]:)<C5FR2-<DWUMJLE?Z$F9C*.HU%^\<04/%Y*ATGR:!%P*M5SHI$
M./-<P%Z8@Q=IXU<:8-6M7)<M,V?<3YQKW5$5<N\;W:"LKJ*ZP0`J$]$,'BDQ
M77@"/(R#]NW7*/<,0!X"1'`'`'`'`'`1VU`Z1M+FJV!][6I33WA[.4.5(R+9
M')N/ZU;74:4W/FI#2DM'.)2$<%$>956:R"I1[H&`>`7GSWV370S,V<^4]$.8
M-1&WSF)DLL]KL_B"_3UJJ$/(*#UI5T8:QS;3(#!,JX`()QUKCT4R]PJ8````
M8/88X[5MMQ+E)2LC8)W<,)1)Q.2#OKUK"YG)#I<RK'4E+-(8YO*\VHF4#)D]
M\5QZ)AY`D?U(A(;&7:?L.4"8C\?[GNC35GML9$6<)QRTQD;&-QO.('KTI1*L
MK%6F,JL'=G""ARB<@H5UXV*D/,71@*)N`N#^U;V[?K88P^C?\[OUZ<^CC\J7
MB;Q1[F\8^Y^`L(X`X#PF1LI8SP_6'MVRUD2C8PIL<'-_;,A6R!IE;9>E$W)U
M-V-_'1J!A*4>0&5`1_)P"\^JOM4FV!@:34HV$)_(&MS+;ER$9"4O3=5G<I7I
M"95.9-JQ\XM@3BX"2174+R!2"3GE!`0Z*1O0X"$C369VH;<J<"GI5T@8UVR<
M(3I!2992U$-A6R,UC7AQ*20(CDB">6!\KWIZ=(\=CPA`,(=%QZ!P#,-([+ZX
MS])QE^W<=Q'51KQN;9QX12H,?=YZCX@@'2@EZYA%)3#^RV(&()B=,#Q`5@.@
M<>2).`N0^QHVU_JR0OT5/F3^7.4OHT_)YY;^N?K?QW[KX"SW@#@-9YJ]VD=S
M3$NI>\:@=RO2EJ&WB\"C8)F5@WVG[5U>COJQ7%)1T[11-3BT>R99B6#"#42(
M=A'0L9&MNJ,0C[H<C\!=YM2[NW9S<8N&F-\4X5J>VAF1)0(.9C]0N+VM:LZL
MHF)6CN/E]1[ES<3J-T3^EYV6;B51YCS0*/,.`;FJENJ=\K\7;:/9Z]<ZK-MB
M/86S52:C;%7Y=FH'--W%S,0Y>1S]LH'H*)*'*/Y!X#T/`'`'`'`'`0JU7[<N
MAO7##N(G5/IAQ+EU=9`S="TS59;QN0HLADA1`8/)->-$7V$,0@]SO612`>0<
MP$`Y<`O?;^S'Y(TO6*1R=LZ[DNH71=9#+J2(8FR#/R5[PY,+^N%CY)U%=YKF
MAR'(7F$["VPX@'INEP$6;-VAO<5VI[E"XDW2\?:/=7D4J_4BC93T;ZA,;,\O
M-P;D'KG]LQ&T>G5(MR1,)"NZ[3FQS&`G7";ES"YG\19H>^`^HK[OO[1OR*I'
MQ._!#XR/C*]S^*_=W`7Y<`<`NMJU[4AM(Z674U7(K+MJU)9`A5WT>YINGNFO
M;&W1EF2ZK11B[O=I6J&/?2NDA(<S63>')RY]`?0$*W#;V^_%N"%!CMB[3LAA
M['TZJ1M$9[U(I/WS$62Q`$)V(FKP;$F+"F1(<%#))!9BE[A0*H(\A#OX_85W
MB==)49/=;W?;W$U&2Z;B6P'I?4>(5]1%R;T\8^-'L,88N8N4$!$G3"MSQ/0`
M%#AS$0M1TJ]FSVA-*0QDG&:8(O.-UC5$7`7G4I*N<OR#EVCT3$='J,LFTQ<U
M6*L7IE,W@$3%-W>?`7&>9#"WR0XO\BO-KY`53XNO@#XI\BOU5[1]BX#*'`'`
M5OZ:=H[;:T?R;JVX3TD8@@KPO)2$^]RA;H3SCY*"3D'J\I(2#?(&1G%FLD(1
M1TN8_5,7+5LF7D4B92E``#WN3=S;;IPQ,+5W*FN?2=1+`U5,@\@;%GS&3*:8
MKD/U9T7\4:R&?,52G[@E63((<!-*'F(JPQ$5/P4BRF(2<C6,Q#2T:Y2>1TI%
M2;9)['2+!V@8Z#ID]:+D524(82'(8#`(@/`=CP!P!P'T44313.JJ<B221#**
M**&*1--,A1,<YSF$"D(0H"(B(\@#@$4;G.:Y>U!ZK<\8MP5GFQZ3-H/31>%L
M:3]NJW?8SNH>R,%1*Z6481K^)-=Y&R,TO"+6/D'9(*N0SADLX;N)!<"KAA_>
MK[.AMU;<&U-F+4'A=AF6U9TH4YAV,B<AY(R6M)BH6UY/J=5L)UJE7(FLTX2/
MHJ67*0HLC&0,8IBGZ1>8@\EI.^BSII_X`8;_`*.JYP%>^_C7<QR^TWK!L6!<
MN9*PMDS%>/#YAC;;BRVS5+L3V`QN];V*]UAS,UYVPE_!,_1&\DDHDBLF)EP2
M,(B!1*8%5OQ,>7_A*?[CS_'#]/CY2?\`U/8>`V&'`86U),;')Z=<^1M.Z_WW
M2&%LIL:KWL)@<^^-W1IU"#[W$OI@7\)J)=#EW>ERX!?_`+(\6J$V9L:)5\C-
M.=1SAGU/(B;<I".R7$MU-WJ26*``H$@6B#"``'].#;J@]#EP'NNU9?<DZF_X
MXZ??Z<Z%P%W&EIN9GIDTYM#F*<[7!&(FYCD`0*<R&/Z\D8Q0-Z8"F$O,.?=Y
M<!%?>#OU:QGM7[@]LMCE)M#DTCYRKI!6.F0',W>*%,T>K1R8J_O8N9:SV)FU
M1`?5*K%#T1X#3V>9#+7P8F/H<^>_UIQ\4OPG]#Q/^Z];X#>9<`<`DMEOYTG9
MF=:.<]06*<(VG4/LX:OKRKD_)E+H"1W5CTKY-E3B,T_8"J!FE;:-U%CI1RD@
M9"$FHCO2.7>-7S%!<0X6^IO.[;VX3LKYZJ^FO4G5IK*-CL."I!KA2WM9*BY>
M1\%9CI4M--R4ZQM6BLT:$CFBJSE>*6D&1$DS'!<Q`Z7`7IUC>=VK-/&FC#2V
M3]>6FYJ^@,*XV1DJY3\C0^3;BB]84>$2=QH4[&JELLQI-!P04CH=Z@HFJ`E.
M!1`>0+:ZM-9^HWM16;JEH"T!4#(6+MN&FWRO6C5)J;NM?-%'LJ-?>ED&*DBB
M"CF-BVC!(.^JU53.%9::E^]WSY-HV9F%J#:7V4.AOY'(WZ"WV<WJT?HN_!?V
MIY0?K7VU^?@+&^`.`XSUDSDF;N.D6C9_'OVR[-\Q>H).F;UFY2,BY:NVRY%$
M'#9PB<Q#D.42G*(@("`\!2SJ%[.ULZZE9N0L]UT7T:HV>5<JO'\WAB;N&%>^
M72YA47<K0&-K!7:BJNNJ83G.>.,<YA$3"/,>885QMV6?94QS.MK`?2]-W]RS
M5*LV89)S)EBRP0*$$!+WS`HVR,B9)(#%YBFZ173-Z!BB'<X"]3%.(<58*HT+
MC+"V-Z/B?'==1ZB#I&.ZO"T^KQ9!`H*&:0D"S8QZ2RXD`RJG0ZQ4_ICF,81'
M@,B\`O9ND6/M#L3J1AVNUC0=/MFTV#BNL+3$CE%YBMO8R95//VXMG:HDN=UK
M\N,6E`$B#)"5`4.L.IT3B;I`4*W_`'[=M"^1_1M_I/3_`/\`5'@#W[=M"^1_
M1M_I/3__`-4>`_1*Y]L_4.4A\2Z,D"CSYJJR6!!(7D`CZ8$<FK*=T0Y=PH]W
M@.X96#MF3HXE<4?0S&$`2_OSYYB0Z?(>?2-RCKA(*]$G+N^EY]WN<^[R"IK/
MF_-OZ8,SI5M,$/ES0OJ2U$VB6\`!B'27CH^?K)!6#K#HA6YM_4FHUD;,55,P
M+1S)\]>,P(<72:`%X!AGSN=HP^1+&GW6GG+\4XJ^\2^3'R^];]P^*?=G`,Q\
M`<`<!`?7YN9:.MM+%Y\F:J\K1M45?M7JE(QM#=3.Y7R:^9E]-&T2CH.$G\D'
M7B1)9^X,UB61U""[=H%,!A!1!;.^]GVE^R/ZQIVCIG;FVNGL@^A;#DUTXE6D
MUDJOH+BWD&CVT,!A+-F&:>(`=)2"KIHRIMCB9M)OE3D*L<&D=LS9PT3[5]'3
MB=/U!).95E8M%C?=0M^183>7+J<2)B\:DF2M4F]0JRS@@&)#1";1ER*0RX.%
MRBN8+5N`.`X$I*1D'&R$S-2+"'AXEDYDI66E';>/C8R/9(G</'\@^=J(M6;)
MHW3,HJJH<I$R%$QA``$>`4,W$NTT/I7*1]$.RYBYUK3U56)VM7`RU7H![<\5
M5*0'DV>KT"'C@(7)[V#.KUB\TY6:U".Z`+*+R*`*D('1Z!>S,6C)N44=<>^'
MEF8U>:F[([:V`^#I.RJ63&E:41-WU%Q.29Y$$6UW2@SJ=!&M0I&-/8%*+<"R
M+0P$*#A4)!PM9AHJNUN(BZ_7X*/9Q$)!0D>TBH:'BH]NFU81D5&,$D&4?'L6
MJ14T442$323*!2E```.`[3@#@*TMR+=DT<;7..26_4=?.^+U/L5U\:X(I(LI
MW,>3G1%#-4@KU7,\;!'0(/2BDO,2*K2+0.`I]<=<4T%`5UMV(=YCM%<JUD]2
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M9S(_@3PN[\M/7EOC'\X/A?U`^V_9O\/\W`8F4\"=`WDUZ'_F><'H?][\W`<+
M_,G^QO\`S!X`_P`R?[&_\P>`/\R?[&_\P>`:(_R']2__`,L_^T7K?_U__=X#
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g645012g78y27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g645012g78y27.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X004:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C`M8S`V,"`V,2XQ,S0W-S<L(#(P,3`O,#(O,3(M
M,3<Z,S(Z,#`@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z-CDX03E"-C%%,30P,3%%,3DX,44X,#!$13,V
M.3,P1C$B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-CDX03E"-C!%,30P
M,3%%,3DX,44X,#!$13,V.3,P1C$B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HS861E-C0P-"TP-&8V+30X,F0M.#5A,BUA
M-V8R86%D-S`V8CDB('-T4F5F.F1O8W5M96YT240](G5U:60Z8V$V8V$T-C<M
M,#@V-BTT,SDU+3@R,6(M-3`Y9&$V9#<W.68P(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YA=&5R:6-K/"]R9&8Z;&D^(#PO<F1F.E-E<3X@
M/"]D8SIC<F5A=&]R/B`\9&,Z=&ET;&4^(#QR9&8Z06QT/B`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@4')E<W,@4F5L
M96%S92YD;V,\+W)D9CIL:3X@/"]R9&8Z06QT/B`\+V1C.G1I=&QE/B`\+W)D
M9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@/#]X<&%C
M:V5T(&5N9#TB<B(_/O_M`$A0:&]T;W-H;W`@,RXP`#A"24T$!```````#QP!
M6@`#&R5''`(```(``@`X0DE-!"4``````!#\X1^)R+?)>"\T8C0'6'?K_^X`
M#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"
M`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#_\``$0@`,@"B`P$1``(1`0,1`?_$`(\```("`P$``P$`
M```````````*!PD&"`L$`0(%`P$!`````````````````````!````8"`@`#
M`P8$#A,``````@,$!08'`0@`"1$2"B$3%#%!%38W.",S%AAA8F,T5#6U=K9W
M&3E9&H'!(C)")&15996EUA=79UC8*EH1`0````````````````````#_V@`,
M`P$``A$#$0`_`%S;PW>[DD_;1(94[V!L(P;RLU]JXC%*@95LH"W-RK\IC$4?
MJB+UJ2;A@>*N<6[W:<I)A*<WN[:9\2:(_P!\,\86*^JAVC[#HUV9)(-+)[;=
M2U%":_J.4ZW,D!DTHB<*6.3G!HXX6%-8\O853>1(I<AM<QV;#5PAFK$A*$@@
M.0%X!YPF[NVVU[:<]0O48X7$^W%7S)<M63=?M!+6@MZA[_.)TT2-"11J&XW-
MI`W+VU;*:BPG?OH]5E.6[.BA4<<4,Y('!(>K7+<3M\+],ELY/(W*+O<TD1V-
MA->US=9GY0+[88M57)E3XMQ3#96<6=)U4+C$R&WM87LHPX;6B<W(DI224AQE
M*$O>C1V$WAG>QFQ-8R&7698FGS;4RR6R17.'=]DL8@UX*)9%4T1+BKR^'K`M
M4BE\=4/(UZ!,8$*U.D"I.!D2<L?`Z'_`.`<#^*A02D3GJE!F"DZ8DU0>:+Q\
MI9)(!&&F"\,9SX``'.<^&/FX%,^?4.]+@<Y#GL`I_P`0YSC/@UV,+'CC/AGP
M$&$9"+'Z./9G@?']8>Z6_P"D`J#_`%38_P#N/P-W-1M_M.M\6Z<.VHE\1*\F
MZMEK$W3E5%4TA2@CBV3$.:IB(6AD#*S&#$Y$,RH1>2L&!_`B\<XSX>(;A\`X
M!P#@'`.`<`X!P,:,A<..E">;G1.-&S1(A&V))>8Q-8Y0E;3<#":WIW\27+J2
MA,"8+`B@FX+S@6?''MX"#?J'_4(;@ZM]A;GJ5KE$JAC,1UK!7K\[2&TZ@B=I
MOM@S"80Z/STY0W&3=`Y$1.*(6Q_2HB3&<"-U-4$'F_'!"(HLH,Z[4O4E[+L'
M6QURV+3%1US`[.WRK.PI[9[U/H.VV7#8F&GYL57+TS5_#9VF=XVZ%2N7I371
M.:\D.7P#1E*#R&G'X4EA=!Z;7M)MGM'TSG[A?T)A[18M`6"DJAVD,$C2>+06
M?QMTBZ)]85I432ARR,#ZWI3C4CDB0A`WY+PG.*)("?DD`,&QB(1.$MF66&1>
M.Q%FRJ/6Y:8PRMK`V96JLA$J5Y0-29(E^*4B#C)AGD\X\XQXYSP,BX!P#@>1
M>C+<$*Q`<(825R10C-$7G&#`EJ21DC$#.<"Q@>`CSX>.,X\>`F9<WHZNM>"U
M5;%B-=S;@J7B'5[/)FVIETYJHUO.<X_&W5\1$K"RJ=(4FHQJD@0F!":`8@>.
M,#QG/CP%I_3C=-VM';O)-LF;8V:7%#T]%,=.N<2'4CY$V0U>=8#A8Z5Y"^CE
M,.EX5!:8N()OA\$A(R'(S/-D7B'&`N?W!E+EZ2V<4_3G7>6EMV.;Y'K95;*S
M;$LR:.\?<*>=V.+1HF"**P-J9(VI%R"RUPEF%I#@,9I1.2Q%A"((P?T+%D99
M8\^'B(`19\/D\1!QG/A\OL]O`^_`.`<`X!P#@'`.`<!"[U(6^/3K#-[(C5&Q
MG7,IW.V'J5DA&;?L5ANJ3Z^XCL9>$94JC==.CA"4ZM7:[FECST2N]PY@3I6\
ME:6G*4YR,\L@&-XWJMU9]S?73JPO5:\1R0:JFP5K>-?XLE3KZUE-))VPK,1>
M(?''2!NS:Y118P+X\8TNB1&L-;UAJ#`A_$!`29P+`]3-/-;=&J=::&U8JI@J
M2L6E:J=LLC,-P7+7A_<"DQ+C))-('I8Y2"32)P*1D@-6+E)YWNB2R@Y"446`
M(;+\`X"=6POK#M7*-W?DNMR'72>SRAZXL-SK"Q]B6N8-Z%W)>X^]&Q^52&$5
M:='E`I1$F!T2GX+,.>4*MR)*R:24'`BPF`X&S/#7(6=J?V1<0YLKXVH7AH<D
MH_>)7!K<TI2U`N3#\,><A6D/`8#/SA%C@?I<"#MG?NU["_Q'6S_`)_X"(WH<
M?KYV.?O1UC_=F\.!X/6\KE+9=G7,Y(C/=+&^!7XN2&Y``S!2E)+:H/(,R68$
M98_(:7C/@+&0Y\/#./#@1!7W6/ZJ39BI&?><.Z=M1B<26/IK#@=/R3:^R*\M
M%\85Z3+NSX;J_8$J.HX6>]H3BS$C.X*VSR`-"6H*3"_N,!>/Z:WNKO7>%PN'
M1;>?WHMP=<6I8]():Z,J:+R>P(9&9"FA$W9[`CZ9.@1H[+K25+4:=::2G($X
M)UF!FDA4)5)R@*P=Y>Y[M3[1-^)]H!TH'O</KFJGB0,SQ:$%-CK%*9V3"G/$
M?EUGR:UI1CZ/K&IT\A-PG9@H3DBQR`(DP9IYRLE"0&/_`,F!ZOCY?S^I3CY_
MOO/WL_V?X>S@,$[C]CUJ=*/3E0,[VE5)KJWJ55[`Z8;&Q^E2R5H;!V$S%SEL
MKE\ME9`DKJ^1&,I6U2XN*HK)1R\S!"0)I)BL!P`6FH6N_5I=DD29-P(QLO/Z
M>JBR5)$FAB%?<S)KI'7F%'G`5)WJ(5M$V_XI+##4.?%$M<DH3'!+@)X#%18\
M'#"0]F^XOMW[AMVYYIWTLN$CK^D*I/<$IEE0I4PQ*13-DC:[Z!<;?L:X)%YP
M0"&R)ZSGZ!:VPY*M5IA%Y,"J4B$40&KV[U%^J0Z^M<ICM+L/V`6FBJJ#.42:
MGT^(;>223/\`A7-),UQ)EPC9@)D8U0,O#N3@W.#,9+*R(?AG`<\"H_\`EE.U
M[^D.VS^QCZ?^V"3?MI^R_P!<_C_U3\;^FX'9-X"%?J0M&>FB2;V16V=F>PF4
M:?[#W#'X:=:]=0RE'K80M\C;$C(B,;L1Z;HJI;UM4+5["S%(O?KC%I2\I`$\
ME#G(#S#08S9-J^KCI7ZXM64BJ_FEJU7)A30R:_21O-669,+P+>P#F+K+HZV0
M=K5JY,I?EDA->'18F2)VU"-=@(\IPC)*R%@NHNX^MV]E*L>P.K%GL]J5>^JE
M;7AW;D[BUN3(_MP"!ND9E,<>T;<_QB2-H%10S4:U,2;[HTLX&!DFE&##9S@'
M`3TV`]'=J3>&Y\KV-2;&6=`Z8L>Q76S;`UZ:(FS+EQKQ(WLR0RA@A=IJ7LD^
M+15Y<U:C)11S,X*F\@WW1)^<!+$6#?#(S-<<9FF/,:(AL96%L0,S.VI0Y`F;
MVMK2E(6]$G!G.<A(2)"`%@QXY\`AQP/T^!!VSOW:]A?XCK9_@$_\!$;T./U\
M['/WHZQ_NS>'`]WK4BBC]DNL4DXL!Q)T?N4HTHT.!EFE&3RH`&%F`%C(1@&'
M.<9QGV9QG@=!5,6`I,G**``LLL@HLLLL.``+``L(0```.,!"`(<>&,8]F,<#
MGK=:+?@_U=G80T(C1-0'5UW<2C.0XP2(HUR=6@XU6$`/($9_QIGQ&<Y_OCL>
M;/M]O`6_UBTNI>/;]WAI3V#;?SOKY?(3)99`RK;!#C'^'KYS&)$(LEMG[@=*
MX@*-Q:8,W@Y-#Z:,UL.",H1@RRE!1W`OCST1]60@Y_\`9<J?.!!_PI94&<9Q
MG'SA_.9QXXSC/R?/P)!]7*FB3'I;TP1:M[0;KCKF.P*SX[%;18W%$YLEFM$1
MK;7:-M$]2+6MQ=6Q8"0HT@E03"5*DO'Q`L!-'C.19!\"&P@N1ZD16MX^:1&2
MG[7-CA#(<A*PF31\MTK-*PMIJ,A.$.""&H)X,E@+QCRA+Q@./9C@<^GTP^]-
M#]4.T&[VD^_2]KUQGDZET3CI%D3P`F>,Q^>T>X6!'W^O9M(5!."H\VNX9-\:
MT.*D1+88(DW`S@B4)O.%UOJ8M_\`1F^^G_8&M*1W!UJMNQ'B:4.K:(-7-T5_
M,9:Z)FBYX6Z.I[>P,#\O<U93:V)35!X@%Y"424(8LXQC.>!S?/\`Q_X'=XX'
M/Q]1#Z?K;/9SL+=-M:%L2CG2(;+@K^/J8Y<5S1>IG^#S&&PR.0(]`T%S52A3
M2^,KF]C3+22F<:MT*/4'%919"$HPX,[[5/3=;(O'6QUS5[55W57++#T+K2Q(
M%:2&RYXBJ^"R?%PSHBPW1X@$VG1C9'6LF+2I28U)RGDUMRO:0)18&4<1A,8%
MTOIK.K6VNL73B=M=WSN%RJPMA[%06F?'ZUDA<Q@D+CR",(8_'T2*6)`A:))(
M'8DHU2X*V_WB#W?PY))Q^"<G#!B[@'`.`<`X$1W^?$DM$74HGR]Q:H,54UB#
MF3DT!3#=T$6Q$'C#^K:2UF,I#'1.UY-$G";C(!'8#@7LSP*.>A+K)TAT0I9_
MVQU#N^Z[$K;=6KZ6F'Q5_+:Z;U<;CS8B?I'%BE".'QYA(87]2380@+TRE0IR
M48$L`?#.,Y$$Q]J73/JGVSRB@+;NZ\[,KPC7E-*&V*JZLD-=IHZ]9E+]&75<
M%^72N+R8`STZV*E$E83'$>&#!X%C(O+D(6%%;K:_!V?=]1CY7E#9K%1$3V%/
M=W`38CKY7`9E8<@JUB3-TQ.=`I%LI42R,*BQ(`E^;W6`B"(6<Y#@*]:=Z8-5
M]4NRFWNUHN\;/3VG=3O98GR'SM^KMMJ=O<;B5(S7!"RBQ%FF1>^3G(O*A+.<
MSAB\V<"]YG&.!D79YT>==G9DK26-LI%G2N[;:&Q*P)[]J^2M4!G2IH38$6UL
MTK4O#8]129(D&1>1)]*(%*I*5^"3G%%YR'(+NV/Z4GJ<JV^]7]<9+M-O.=8>
MW@KAQ3YK-BEG.-'AH^!I;'FIDB?2ZL`6RE"C2L`D(O(;A6=GR8\OR\"Z+;WT
M]NGNY>M6CVF4\OV[8TQ:%U\[PBMU<0?*R+GDK97IBA3*>YSE&\0EV1FJ2TL(
M2F`&A1HBO,<9XAR'(<!"^-H,B5;1R+0U9)FQ`0P1UG8VP3^[-J%>M0LB%.U$
M*C`&F)0FFF`38\XBP8!Y\Y\,8^3@4);E=1_5[W3/]OVU:5;7%1=R4;;<PUTF
M=\L"(NEY1.'2LTS`5EZ&7+&J00RV*[^&=TZ=ED:A`)0>22).0I"23@O`5KB]
M&;UD`;RW86X^TH6HU2)&4YBF-"8;S58`B&-*6LS5GPPU(0!SG(,"R+&,9SX<
M#)?ZHAUE_P#>;L=]2?R.^O-#?M9^SOLV_7'Z/XK]+P'*N!RZO5@:Y[W2WM0=
MID^5W<-F47+H16[#JTOB45E,OAS:U)HJSIIC!6,IB1N2-LF)EEA<UBU%G!:Y
M6%60?Y1%#)S@)<[M]9NU\SJ%Z>VRYH[=<Z8JMJZ<(]E(LA2O\H?H38*]]2&4
M2KNIL;<.#F:[1ZFAE,A:UP"9AM<R%A!YA:E7C!H,`>D.J;;ZJ.NZ?I=E&.?P
MZNI)=*Q^ULA=DH75I?&R$G1QK!+7MC9'P)3HR0>32W`SD!(BB"3U12M82`0%
M6#30:YX!P#@'`.!`VTM+,^QNMM[T,^M#4^MENU-/8`8TO@U);.K4R6-N+:W!
M<C$9A*HM&4XGE#&(L6!XP'QQP$*9MHM>S'J=UP0A9I/L)6VMU"-MP5[N[1&-
M3K$VB)<M[FJ.P%@%M/)-?*]O2K'B\ZQMA@;BBXU*FMV6L[*I"H\$P!&Y\X;9
MEZW5VU1W161[*Z#;6;-]8\4H[8F+IM>:.TWNZCE=3[EN^PCP]9N.T]'PVS,;
M-^@9I5QX6ID=E3R\(B5(#E@"DV%H,`#:"B^L/1G=#L%B3H^]>%F0O0R(=6;&
MP496%]U3:M0-4"M1[W!OS$\:W!F>W)*Z-MD?13NH=D2=2N,6)$#P!Q(`7DY.
M<`,!Z_\`1ZQMV+!U%I3M#HB[[:UXUTZ[+N20>+;#,]ELL/:KH_/NM:H8@XR9
M6I&Q8?+81ZH1:/EM)BTT:XAD&4X$!P(T"C@:^0ZAK0#!-%';M*TYW?W7T:J*
MH-M:+B=,1&"6S8\WIZZ(5N%8C-2UE733S`ZQV>3UBD.J;8R,D8?U)2Q(C3D!
M,\G^,!/R$U:WZ_[54)--*]M(MJCM)$].*@WVW5:M<=:I&R.]B;%ZJZK;<ZX0
MVG*SF4BK%V?%\R9ZJ9KN;G-[6QPU2I7QED6^\&(TL>1Y#59MU.D)=2Q2KF3K
MDWZ:>_\`0W@Q.+_V)+VFSC*G#9Z6YR7:4[%..U1LL!5$@H]UK4)Q86,*')1R
M$X#>%+DP/Q60P7M>IJ"5U4O:G(-^=)]HK0WLD]W3B5:O;^XK^P[#UI8=?GZ=
MQ4&OS+&[&9)%FO:.:8%$#QLJEC7I,J"7(W\(8H&<$)099MAI[N?*UD^?I%35
MX272XGMR[`[#N"L6K6NQ]B?RG%-X%0Q&N]YN6M<5LREI;>52%F-3RD;E[<[F
M(&A=D:G)2CSX+X'FO+4BB95K5IFA24EN$R+ZT6[)KT-6LG25?THUN>SYK-XP
M!P?I]K$JV$6S:K[$&ECB1.D?RI6H-=FP`AEIB@8\O`TX_P"`VW?_`,WU$?8Q
M](?=9V?^IO\`SQ^\7];O^CWUE_RC@=-K@'`.`<`X!P#@'`.`<`X!P#@'`.`<
M`X',3V+_`)\"U/J3_.2NWWOONE_;:+ZZ_J'^:/\`2/P_`Z=F/DQ_:^3^QP#@
$'`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
